- DRL net dips 68% on price pressure, writedown
Dr Reddy’s Laboratories (DRL) suffered a 68% fall in Q4 net profit ended March 2008, after writing down the intangible value of the product...
- Glenmark gets nod to sell Zofran generic in US
Glenmark Pharmaceuticals has received final approval to market a generic version of GlaxoSmithKline’s popular anti-emetic drug Zofran, that...
- Glenmark gets USFDA nod to market cancer drugs
Glenmark Pharmaceuticals says it has received the US Food and Drug Administration approval to market two of its cancer drugs.
- Foreign buys, new products pep up pharma sector
: Buoyed by overseas acquisitions and new product launches in regulated markets, the pharma sector recorded exponential growth in the fourt...
- Dr Reddy’s logs Rs 325-crore net profit in Q4
Hyderabad-Based Dr Reddy’s has crossed revenues of $1.5 billion or Rs 6,500 crore in 2006-07 against Rs 2,400 crore (FY06) piggybacking on ...
- Generic vs generic: Drug cos battle to protect turf
Generic drug makers, which have typically waged legal battles against innovator pharma giants, are now suing each other to protect their ma...
- Pharma may prove to be the Little Miss Sunshine
Buoyed by overseas acquisitions and strong growth in key international markets, pharma companies could see an overall 38% increase in net p...
- Windfall for cos eyeing US oncology market
With anti-cancer blockbuster drugs set to go off-patent in the US in the next three to four years, generic players are gearing up to tap th...
- Dr Reddy’s Q3 net trebles, 9-mth revenue crosses $1bn
Dr Reddy’s Laboratories has gained entry into the $1-billion club with its nine months’ revenue of 2006-07.
- DRL's generic version of Zofran likely to generate Rs 200 cr in 6 months
Dr Reddy’s Labs’ (DRL) generic version of GlaxoSmithKline’s (GSK) Zofran could generate revenues of around Rs 200 crore ($45 million) in th...
- DRL gets US nod for multiple dosages of Ondansetron
Pharmaceutical firm Dr Reddy's Laboratories Ltd has received approval from the US Food and Drug Administration to market Ondansetron Hydroc...